Full text of this paper is available at http://www.jstage.jst.go.jp/browse/dmpk "What is the role of drug metabolism and pharmacokinetic (DMPK) research?" "Where is DMPK science going?" "What is required of DMPK researchers now?" Such questions on "the definition of DMPK research" seem to be often discussed among pharmaceutical companies these days. Looking back to some recent conference themes chosen for the JSSX Workshops (WS) and Annual Meetings (AM), you can easily understand that such kind of questions are now prevailing over DMPK investigations in the pharmaceutical companies. For example, the WS held in 2012 focused on collaborative DMPK studies addressing drug safety (toxicity) issues, which may reflect a recent trend of DMPK seeking for a new region to enlarge its contribution to successful drug development. The WS held in May of 2014 picked up topics on biopharmaceuticals, which may be symbolic of the paradigm shift in exploring medicinal seeds that has had an impact on DMPK research. Indeed, during my dedication to DMPK for about 20 years in pharmaceutical companies, I recognized that the roles of DMPK in the drug development process have dramatically changed. I myself have often wondered what I should do for successful drug development as a DMPK researcher. In this editorial, I will briefly review the history and transition of the roles of DMPK in pharmaceutical companies during the past two decades, and also give my personal perspective on the future by relating DMPK research to innovations in science. I will be grateful if this provides readers with a hint of how we should be engaged in future DMPK.
Still Need "Human PK Prediction"?
The key original mission of DMPK research in pharmaceutical companies was to design the optimal medication by analyzing the time-and spatial-behaviors and fates of the administered drugs. However, the philosophy of DMPK research has evolved in accordance with scientific innovations occurring in the pharmaceutical field. What raised the presence of DMPK research in drug discovery processes was the introduction of combinatorial chemistry (CC) and high-throughput-screening (HTS) systems, which were widely proposed in the 1990s. Nowadays, in-house CC and HTS systems have been conventionally employed in most companies and worked out for picking up drug candidates with promising activity and fewer undesirable properties from a vast diversity of compounds. These systems could rapidly produce a huge amount of information on compound specifications as well as chemical structures, and such cumulative knowledge and information were fed back to drug design in pursuit of drug-likeness. This has promoted "medicinal chemistry," which is defined as a drug design based on a quantitative chemical structure-activity relationship at the molecular level. In this trend, drugs that may have liabilities in clinical DMPK properties can be screened out from a candidate list even at the early stage of development, which brought about a new concept of "exploratory DMPK research" in pharmaceutical companies. Accordingly, quantitative relationship analysis between chemical structure or physicochemical and DMPK properties by means of the data mining method became popular as a significant part of exploratory DMPK research. With an advance of exploratory DMPK research, came the boom of "human PK prediction," which was the very start of "translational research" and would become an increasingly important mission of the DMPK group in pharmaceutical companies. Therefore, the 1990s may be called as the time of "human PK prediction" in pharmaceutical DMPK groups. In particular, drug screening in terms of membrane permeability using PAMPA membranes and of metabolic stability against cytochrome P-450 (CYP) enzymes using in vitro liver microsomes made it possible to exclude drugs with expected low bioavailability at the early stage of development. In only 10 years after such screening systems were first introduced in pharmaceutical companies, drug attrition rates due to DMPK liabilities were remarkably reduced. However, despite such a great achievement in exploratory DMPK research, especially focusing on human PK prediction, it seems that passion for human PK prediction has been gradually fading in recent years. Why? One reason is that the major concern about low permeability and CYP instability has almost gone away as mentioned above. Another reason might be that many DMPK researchers have begun to be aware that there exists a limitation to predictability for human PK properties. Indeed, quantitatively or semi-quantitatively, plasma exposure (i.e., AUC) or bioavailability in humans has come to be almost predicted from in vitro evaluations, but dynamic profiles of plasma concentration still remain only imprecisely predicted even with a well-advanced model-and-simulation technique. However, this awareness of limitation might have an important significance; that is, since DMPK researchers have begun to compromise on their core mission of "human PK prediction," they have been afforded the opportunity of turning to another mission contributing to drug discovery and development processes. As a result, DMPK research has been expanding its field of activity. On the other hand, while theoretical or empirical drug design for stabilization to the CYP enzyme is attained, the importance of metabolic enzymes other than CYPs becomes increasingly conspicuous instead. It has been reported that about a quarter of top 200 prescribed drugs in the USA are metabolized predominantly by non-CYP enzymes, including flavin monooxygenase (FMO), monoamine oxidase (MAO), alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH) and aldehyde oxidase (AO).
1) DMPK researchers are now facing more difficult issues on how to predict the impact of metabolisms by non-CYP enzymes. Ironically, they are struggling with what resulted from their success with the CYP enzyme. Anyway, DMPK researchers have to continue to attempt the more accurate predictability of human pharmacokinetics.
DMPK with Computational Science
In the 2000s, many epoch-making discoveries, innovations and changes of outlook took place and affected DMPK research. The information technology (IT) revolution in the early 2000s might be one of them. The explosive spread of personal computers (PCs) has changed the style of mathematical analysis of DMPK phenomena. As the user-friendliness of PCs increased, DMPK researchers became inclined to work more at the desk. The tremendous increase in memory capacity and calculation processing ability made possible an optimal answer to any complicated mathematical models in several seconds, while it had taken more than a couple of days for the same processes in the mid 1990s even when using a huge host computer. Now, the computational analysis, which used to require some mastery level, has become a powerful tool which everyone can access easily. The IT innovation is likely to keep going forward forever. Allegedly, the supercomputer "K" developed by RIKEN in Japan has recently been successful in medicinal seed discovery. The time will soon come when an innovative drug will be discovered at the desk. Likewise, the in silico screening and optimization of DMPK liability may become a major part of DMPK research.
DMPK with Microdosing
In the mid 2000s, a new concept of human-based exploratory clinical trial represented by a single microdose study was proposed. Even if DMPK researchers try a lot of in vitro evaluations for human predictions, all clear answers will be obtained from clinical trials. Since an exploratory clinical trial can make it easier to translate non-clinical information for its clinical application, that may push DMPK researchers further back from "human PK prediction" in non-clinical evaluations. A radio-labeled compound is commonly used in microdose trials. Bioavailability in humans can be one of the most fundamental bits of information in PK(/PD) analysis and can be obtained by intravenous microdosing. The information can provide important insights into effective design of the later clinical trials. With the recent advance of accelerated mass spectrometry (AMS), DMPK properties in humans can be evaluated even at a very low dose. The major issue to be addressed in microdosing studies is how a non-linear pharmacokinetics, if any, is precisely understood and handled. However, it is well known that this issue is likely to be solved by great efforts of DMPK researchers. Recently, the microdosing study with a nonradiolabeled compound has been attracting attention with an increase in the detection sensitivity of mass-spectrometry. Till now and also in the future, advance in drug assay technology will be a key to trigger innovation in DMPK science.
It is often insisted that the strategic approach should be taken at the earlier stage of clinical development to demonstrate the proof of mechanism (MOA) or proof of concept (POC) of candidate compounds. To address this, especially for drug development in neurology and oncology areas, the clinical positron emission tomography (PET) study and functional magnetic resonance imaging (fMRI) are increasingly attracting attention as powerful tools for clinical diagnosis to prove that a drug distributes and exerts its pharmacological effects at the target site, so-called "target engagement." The key success factor with the PET study is how an appropriate PET ligand for the target site should be developed. Essential properties for the PET ligand to possess include high brain directivity, short duration in the brain, and non-productivity of metabolites that can be a competitive ligand to the target molecules. 2, 3) As selection of the optimal ligand essentially requires a DMPK perspective, DMPK researchers can exhibit their responsible performance for the ligand development. Although the intracompany position of a DMPK group or the method of collaboration with other laboratories in the company varies on companyto-company basis, building a tight collaboration with members of the medicinal chemistry group is inevitable. The exploratory clinical trial has just been implemented and thus is still in the learning phase, but it will be better recognized and more popular in the future. DMPK researchers should be on the lookout for the whereabouts of a future trend in clinical studies.
DMPK with Bio-engineering
As completion of human genome analysis introduced a new paradigm in the drug discovery process, called "genomic drug discovery," the evolution of bio-, genetic and regenerative tissueengineering is attracting attention as something that will affect future DMPK research. To begin with single nucleotide polymorphism (SNP) science, comprehensive genetic analysis for metabolic enzymes or transporters has already been carried out as a part of clinical studies to assess the existence of genetic polymorphism in DMPK properties, to recruit patients based on genetic background or to aim at personalized medicine. As for iPS cells, following cardiomyocyte, neuron cells and so on, human hepatocytes generated from iPS cells may be soon ready to be launched into the market. They will be explored as a useful tool to clarify individuation in the hepatic metabolism of patients. Humanized animals represented by the chimeric mouse with humanized liver or the HAC (human artificial chromosome) mouse are capturing the spotlight as a human-in-animal model and are expected to fill a gap in DMPK characteristics between laboratory animals and humans. On the other hand, cell culturing techniques and devices based on microelectromechanical systems (MEMS) are advancing surprisingly fast. With that technology, various types of cells can be controlled at the single cell level and aligned on the micro device plate. In addition, microenvironmental physiological conditions linking each cell such as body fluid and blood circulation can be constructed and reproduced on a microchip. This instrumented "human-on-a-chip" is being developed with an aim at an accurate human-mimic model with which a whole process from oral administration to exertion of pharmacological responses can be evaluated at one time. 4, 5) From the perspective of animal welfare, such an alternative in vitro method will be further developed in the future.
It is often said that DMPK research has already matured and thus it has become difficult to make breakthroughs in that area. That may be true as long as you just stick to traditional concepts, methodology, empirical rules and cultures that have been passed down in your company over long years. However, as I described above, DMPK research has evolved to date with a trigger from lots of scientific innovation. Accordingly, a DMPK group in a pharmaceutical company also has had many chances to change its business model. As a result, the roles of DMPK research in the drug development process are no longer what they used to be. Then, you may ask, "What is next?" To get an answer to this question, what you need to do is to always keep an eye on scientific innovation that occurs on the boundary of DMPK and other scientific areas, and then not hesitate to step into the new field. Our future is out there!
